Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
International Journal of Cardiology
|
March 19, 2021
Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption
Teruo Jojima
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
January 9, 2014
[Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes]
Teruo Jojima, Yoshimasa Aso
Journal of Atherosclerosis and Thrombosis
|
February 25, 2010
Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo
Chie Aoki, Yoshiyuki Hattori, Atsuko Tomizawa, et al.
The American Journal of the Medical Sciences
|
April 2, 2021
No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan
Yoshimasa Aso, Toshie Iijima, Takuya Tomaru, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
July 11, 2009
Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma
Ayuko Nakano, Yoshiyuki Hattori, Chie Aoki, et al.
Journal of Cardiovascular Pharmacology
|
May 9, 2006
Aldosterone impairs vascular endothelial cell function
Yuko Hashikabe, Kunihiro Suzuki, Teruo Jojima, et al.
Anticancer Research
|
December 31, 2021
Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet
Ken-Ichi Inoue, Hidetsugu Yamagishi, Teruo Jojima, et al.
Diabetology & Metabolic Syndrome
|
July 28, 2016
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima, Takanori Tomotsune, Toshie Iijima, et al.
Journal of Diabetes and Its Complications
|
September 5, 2020
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
Shintaro Sakurai, Teruo Jojima, Toshie Iijima, et al.
Experimental Animals
|
December 3, 2020
Time-restricted feeding prevents high-fat and high-cholesterol diet-induced obesity but fails to ameliorate atherosclerosis in apolipoprotein E-knockout mice
Ken-Ichi Inoue, Shigeru Toyoda, Teruo Jojima, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
International Journal of Cardiology
|
March 19, 2021
Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption
Teruo Jojima
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
January 9, 2014
[Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes]
Teruo Jojima, Yoshimasa Aso
Journal of Atherosclerosis and Thrombosis
|
February 25, 2010
Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo
Chie Aoki, Yoshiyuki Hattori, Atsuko Tomizawa, et al.
The American Journal of the Medical Sciences
|
April 2, 2021
No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan
Yoshimasa Aso, Toshie Iijima, Takuya Tomaru, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
July 11, 2009
Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma
Ayuko Nakano, Yoshiyuki Hattori, Chie Aoki, et al.
Journal of Cardiovascular Pharmacology
|
May 9, 2006
Aldosterone impairs vascular endothelial cell function
Yuko Hashikabe, Kunihiro Suzuki, Teruo Jojima, et al.
Anticancer Research
|
December 31, 2021
Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet
Ken-Ichi Inoue, Hidetsugu Yamagishi, Teruo Jojima, et al.
Diabetology & Metabolic Syndrome
|
July 28, 2016
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima, Takanori Tomotsune, Toshie Iijima, et al.
Journal of Diabetes and Its Complications
|
September 5, 2020
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
Shintaro Sakurai, Teruo Jojima, Toshie Iijima, et al.
Experimental Animals
|
December 3, 2020
Time-restricted feeding prevents high-fat and high-cholesterol diet-induced obesity but fails to ameliorate atherosclerosis in apolipoprotein E-knockout mice
Ken-Ichi Inoue, Shigeru Toyoda, Teruo Jojima, et al.
Page
of 6